 Ellen Burnham
Concepts (514)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 37 | 2023 | 716 | 7.190 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 590 | 2.170 |
Why?
| | Lung | 18 | 2022 | 3595 | 1.970 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 113 | 1.810 |
Why?
| | Respiratory Insufficiency | 6 | 2022 | 290 | 1.500 |
Why?
| | Pneumonia | 9 | 2023 | 568 | 1.480 |
Why?
| | Ethanol | 11 | 2022 | 548 | 1.430 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 251 | 1.390 |
Why?
| | Acute Lung Injury | 10 | 2022 | 300 | 1.360 |
Why?
| | Critical Illness | 20 | 2023 | 644 | 1.360 |
Why?
| | Cannabis | 4 | 2022 | 384 | 1.350 |
Why?
| | Critical Care | 9 | 2021 | 475 | 1.130 |
Why?
| | Gene Expression | 3 | 2020 | 1423 | 1.110 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 351 | 1.100 |
Why?
| | Sepsis | 5 | 2020 | 508 | 1.090 |
Why?
| | Intensive Care Units | 17 | 2022 | 618 | 1.050 |
Why?
| | Cytokines | 8 | 2023 | 1843 | 1.040 |
Why?
| | Marijuana Smoking | 2 | 2021 | 224 | 1.000 |
Why?
| | Middle Aged | 63 | 2022 | 26827 | 0.970 |
Why?
| | Inflammation Mediators | 4 | 2016 | 476 | 0.950 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 82 | 0.900 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 134 | 0.900 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 374 | 0.900 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 323 | 0.890 |
Why?
| | Acetates | 2 | 2021 | 95 | 0.880 |
Why?
| | Stem Cells | 5 | 2015 | 546 | 0.880 |
Why?
| | Mentors | 4 | 2014 | 158 | 0.860 |
Why?
| | Adult | 57 | 2022 | 30656 | 0.850 |
Why?
| | Smoking | 8 | 2021 | 1392 | 0.840 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 159 | 0.830 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 496 | 0.830 |
Why?
| | Humans | 118 | 2023 | 115042 | 0.830 |
Why?
| | Lung Diseases | 3 | 2021 | 703 | 0.820 |
Why?
| | Hospital Mortality | 6 | 2020 | 776 | 0.820 |
Why?
| | Hospitalization | 9 | 2023 | 1754 | 0.800 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 225 | 0.790 |
Why?
| | Burnout, Professional | 4 | 2022 | 321 | 0.760 |
Why?
| | Thalamus | 2 | 2021 | 75 | 0.750 |
Why?
| | Female | 73 | 2022 | 59613 | 0.750 |
Why?
| | Male | 71 | 2022 | 55731 | 0.750 |
Why?
| | Case-Control Studies | 14 | 2022 | 3015 | 0.740 |
Why?
| | Behavior | 1 | 2021 | 91 | 0.720 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 32 | 0.700 |
Why?
| | Hallucinogens | 1 | 2021 | 73 | 0.690 |
Why?
| | Cigarette Smoking | 2 | 2020 | 74 | 0.660 |
Why?
| | RNA, Messenger | 5 | 2020 | 2563 | 0.660 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 414 | 0.650 |
Why?
| | Glutathione | 5 | 2016 | 302 | 0.640 |
Why?
| | Survivors | 6 | 2013 | 410 | 0.640 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 215 | 0.630 |
Why?
| | Respiration, Artificial | 10 | 2020 | 526 | 0.620 |
Why?
| | Epithelial Cells | 4 | 2021 | 956 | 0.620 |
Why?
| | Antioxidants | 4 | 2016 | 530 | 0.620 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 38 | 0.620 |
Why?
| | Physicians, Women | 1 | 2019 | 55 | 0.610 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 109 | 0.600 |
Why?
| | Tobacco Products | 1 | 2019 | 101 | 0.600 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.590 |
Why?
| | Biomedical Research | 2 | 2021 | 585 | 0.580 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 84 | 0.570 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 39 | 0.540 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 10 | 0.540 |
Why?
| | Marijuana Abuse | 1 | 2018 | 212 | 0.530 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 286 | 0.530 |
Why?
| | Inflammation | 7 | 2021 | 2485 | 0.500 |
Why?
| | Azithromycin | 1 | 2015 | 80 | 0.500 |
Why?
| | Glycerophospholipids | 3 | 2021 | 26 | 0.490 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 928 | 0.480 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2341 | 0.470 |
Why?
| | Professional Autonomy | 1 | 2013 | 25 | 0.450 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 163 | 0.450 |
Why?
| | Research Support as Topic | 2 | 2011 | 108 | 0.440 |
Why?
| | Oxidative Stress | 5 | 2017 | 1085 | 0.440 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 817 | 0.440 |
Why?
| | Cells, Cultured | 8 | 2018 | 3896 | 0.440 |
Why?
| | Immunity, Innate | 1 | 2018 | 723 | 0.430 |
Why?
| | Retrospective Studies | 20 | 2023 | 12547 | 0.410 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 147 | 0.410 |
Why?
| | Bronchoscopy | 3 | 2023 | 244 | 0.410 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 13 | 0.400 |
Why?
| | Academic Medical Centers | 2 | 2014 | 412 | 0.400 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 231 | 0.390 |
Why?
| | Asthma | 2 | 2022 | 2051 | 0.380 |
Why?
| | Burns | 3 | 2022 | 238 | 0.370 |
Why?
| | Biomarkers | 13 | 2022 | 3419 | 0.370 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2329 | 0.370 |
Why?
| | Aged | 25 | 2022 | 19119 | 0.360 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1477 | 0.360 |
Why?
| | Personnel Selection | 1 | 2011 | 63 | 0.350 |
Why?
| | Cohort Studies | 13 | 2020 | 4904 | 0.340 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.340 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 79 | 0.340 |
Why?
| | Malondialdehyde | 2 | 2021 | 28 | 0.340 |
Why?
| | Acetaldehyde | 2 | 2021 | 20 | 0.340 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 74 | 0.340 |
Why?
| | Muscular Diseases | 3 | 2017 | 106 | 0.340 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 91 | 0.330 |
Why?
| | Hypnotics and Sedatives | 2 | 2008 | 134 | 0.330 |
Why?
| | Smokers | 2 | 2021 | 129 | 0.320 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 142 | 0.320 |
Why?
| | Anesthesiology | 1 | 2008 | 36 | 0.310 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 184 | 0.310 |
Why?
| | Epidemics | 2 | 2019 | 69 | 0.300 |
Why?
| | Sexism | 2 | 2019 | 43 | 0.300 |
Why?
| | Airway Extubation | 3 | 2013 | 43 | 0.300 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.300 |
Why?
| | Endothelial Cells | 4 | 2011 | 685 | 0.290 |
Why?
| | Betacoronavirus | 2 | 2020 | 253 | 0.290 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 166 | 0.280 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.280 |
Why?
| | Young Adult | 12 | 2019 | 10498 | 0.280 |
Why?
| | Marijuana Use | 2 | 2022 | 167 | 0.280 |
Why?
| | Risk Factors | 16 | 2020 | 8642 | 0.280 |
Why?
| | Deglutition Disorders | 3 | 2013 | 119 | 0.280 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1435 | 0.280 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 976 | 0.270 |
Why?
| | Fibronectins | 1 | 2007 | 108 | 0.270 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 227 | 0.270 |
Why?
| | APACHE | 4 | 2013 | 59 | 0.270 |
Why?
| | Preoperative Care | 1 | 2008 | 318 | 0.270 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 144 | 0.260 |
Why?
| | Pediatrics | 1 | 2013 | 981 | 0.260 |
Why?
| | Immunity, Cellular | 2 | 2018 | 249 | 0.260 |
Why?
| | Quality of Life | 2 | 2013 | 2359 | 0.250 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 48 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 342 | 0.250 |
Why?
| | Coronavirus Infections | 2 | 2020 | 334 | 0.250 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 679 | 0.250 |
Why?
| | Bacterial Proteins | 1 | 2010 | 736 | 0.240 |
Why?
| | Alcohol Drinking | 4 | 2021 | 655 | 0.240 |
Why?
| | Aged, 80 and over | 10 | 2022 | 6357 | 0.240 |
Why?
| | Anticoagulants | 2 | 2019 | 546 | 0.240 |
Why?
| | Internship and Residency | 1 | 2013 | 941 | 0.230 |
Why?
| | E-Selectin | 1 | 2004 | 53 | 0.230 |
Why?
| | Shock, Septic | 2 | 2022 | 186 | 0.220 |
Why?
| | Lung Injury | 2 | 2016 | 198 | 0.220 |
Why?
| | Interferons | 2 | 2016 | 150 | 0.220 |
Why?
| | Interleukin-1beta | 2 | 2017 | 370 | 0.220 |
Why?
| | Pilot Projects | 4 | 2021 | 1375 | 0.210 |
Why?
| | Dyspnea | 2 | 2019 | 218 | 0.210 |
Why?
| | Polyneuropathies | 2 | 2017 | 50 | 0.210 |
Why?
| | Fibroblasts | 3 | 2013 | 839 | 0.200 |
Why?
| | Age Factors | 4 | 2021 | 2894 | 0.200 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 23 | 0.200 |
Why?
| | Double-Blind Method | 4 | 2014 | 1664 | 0.200 |
Why?
| | Epithelium | 2 | 2021 | 297 | 0.200 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 19 | 0.200 |
Why?
| | Administration, Inhalation | 2 | 2021 | 641 | 0.200 |
Why?
| | Delirium | 1 | 2023 | 66 | 0.200 |
Why?
| | Patient Discharge | 2 | 2018 | 767 | 0.200 |
Why?
| | United States | 12 | 2022 | 12226 | 0.200 |
Why?
| | Interleukin-8 | 3 | 2018 | 238 | 0.190 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 10 | 0.190 |
Why?
| | Neutrophils | 3 | 2017 | 1164 | 0.190 |
Why?
| | Cell Count | 2 | 2015 | 304 | 0.190 |
Why?
| | Physicians | 3 | 2022 | 772 | 0.190 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.190 |
Why?
| | Status Asthmaticus | 1 | 2020 | 10 | 0.190 |
Why?
| | Dysbiosis | 1 | 2022 | 146 | 0.180 |
Why?
| | Pandemics | 4 | 2022 | 1321 | 0.180 |
Why?
| | Comorbidity | 4 | 2020 | 1457 | 0.180 |
Why?
| | Phagocytosis | 2 | 2014 | 352 | 0.180 |
Why?
| | Random Allocation | 1 | 2021 | 336 | 0.180 |
Why?
| | Immunoglobulin A | 1 | 2021 | 171 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 315 | 0.170 |
Why?
| | Career Choice | 2 | 2012 | 181 | 0.170 |
Why?
| | Capacity Building | 1 | 2020 | 51 | 0.170 |
Why?
| | Permeability | 2 | 2012 | 148 | 0.170 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 240 | 0.170 |
Why?
| | von Willebrand Factor | 1 | 2019 | 56 | 0.170 |
Why?
| | Homeostasis | 1 | 2003 | 578 | 0.170 |
Why?
| | Faculty, Medical | 1 | 2022 | 232 | 0.170 |
Why?
| | Length of Stay | 4 | 2020 | 950 | 0.170 |
Why?
| | Needs Assessment | 1 | 2021 | 316 | 0.170 |
Why?
| | Cardiology | 1 | 2022 | 259 | 0.170 |
Why?
| | Chemokines | 2 | 2018 | 213 | 0.170 |
Why?
| | Wounds and Injuries | 1 | 2006 | 723 | 0.170 |
Why?
| | Disaster Planning | 1 | 2020 | 74 | 0.170 |
Why?
| | Brain | 3 | 2021 | 2380 | 0.160 |
Why?
| | Animals | 16 | 2022 | 31867 | 0.160 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.160 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 850 | 0.160 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 27 | 0.160 |
Why?
| | Macrolides | 1 | 2019 | 56 | 0.160 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 141 | 0.160 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 387 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| | Atracurium | 1 | 2018 | 13 | 0.150 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 20 | 0.150 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 20 | 0.150 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 72 | 0.150 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 23 | 0.150 |
Why?
| | Cardiologists | 1 | 2018 | 40 | 0.150 |
Why?
| | Occupational Therapy | 1 | 2019 | 73 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2018 | 1138 | 0.150 |
Why?
| | Apoptosis | 3 | 2014 | 2366 | 0.150 |
Why?
| | Societies, Medical | 1 | 2021 | 678 | 0.150 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 138 | 0.150 |
Why?
| | Treatment Outcome | 9 | 2022 | 9122 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 222 | 0.150 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 105 | 0.150 |
Why?
| | Hospitals, University | 2 | 2015 | 170 | 0.140 |
Why?
| | Hospitalists | 1 | 2020 | 174 | 0.140 |
Why?
| | Tobacco Use | 1 | 2017 | 60 | 0.140 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 448 | 0.140 |
Why?
| | Interleukin-6 | 2 | 2018 | 676 | 0.140 |
Why?
| | Cystine | 1 | 2016 | 14 | 0.140 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 164 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 928 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2014 | 4420 | 0.140 |
Why?
| | Interleukin-10 | 1 | 2018 | 297 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 499 | 0.140 |
Why?
| | Prevalence | 2 | 2015 | 2255 | 0.130 |
Why?
| | Disulfides | 1 | 2016 | 90 | 0.130 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 265 | 0.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 510 | 0.130 |
Why?
| | Teichoic Acids | 1 | 2016 | 12 | 0.130 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 233 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2017 | 311 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 140 | 0.130 |
Why?
| | RNA Splicing | 1 | 2017 | 246 | 0.130 |
Why?
| | Alternative Splicing | 1 | 2017 | 188 | 0.130 |
Why?
| | Cannabinoids | 1 | 2017 | 115 | 0.130 |
Why?
| | Proteins | 2 | 2021 | 915 | 0.130 |
Why?
| | Hospitals | 1 | 2020 | 582 | 0.130 |
Why?
| | Patient Selection | 2 | 2023 | 646 | 0.130 |
Why?
| | Inflammasomes | 1 | 2017 | 115 | 0.130 |
Why?
| | Signal Transduction | 3 | 2022 | 4525 | 0.130 |
Why?
| | Cysteine | 1 | 2016 | 171 | 0.130 |
Why?
| | Urinary Bladder | 1 | 2017 | 163 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 97 | 0.120 |
Why?
| | Cholesterol | 1 | 2017 | 368 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2017 | 251 | 0.120 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 926 | 0.120 |
Why?
| | Acetylcysteine | 1 | 2016 | 142 | 0.120 |
Why?
| | Transcriptome | 1 | 2020 | 725 | 0.120 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 140 | 0.120 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2551 | 0.120 |
Why?
| | Third-Party Consent | 1 | 2013 | 8 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 953 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1127 | 0.110 |
Why?
| | Disease Progression | 1 | 2020 | 2389 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2799 | 0.110 |
Why?
| | Competency-Based Education | 1 | 2014 | 66 | 0.110 |
Why?
| | Aging | 2 | 2017 | 1624 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 72 | 0.110 |
Why?
| | Professional Competence | 1 | 2014 | 84 | 0.110 |
Why?
| | Atherosclerosis | 1 | 2017 | 342 | 0.110 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 383 | 0.110 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 45 | 0.110 |
Why?
| | Total Lung Capacity | 1 | 2013 | 30 | 0.110 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 33 | 0.110 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 60 | 0.110 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1317 | 0.110 |
Why?
| | Logistic Models | 5 | 2017 | 1839 | 0.110 |
Why?
| | Financial Support | 1 | 2012 | 18 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3118 | 0.100 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 17 | 0.100 |
Why?
| | Informed Consent | 1 | 2013 | 161 | 0.100 |
Why?
| | Interleukin-12 | 1 | 2013 | 110 | 0.100 |
Why?
| | Cell Survival | 1 | 2015 | 1022 | 0.100 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 54 | 0.100 |
Why?
| | Vital Capacity | 1 | 2013 | 257 | 0.100 |
Why?
| | Prospective Studies | 6 | 2021 | 6232 | 0.100 |
Why?
| | Serotonin | 1 | 2014 | 296 | 0.100 |
Why?
| | Neuregulin-1 | 1 | 2012 | 40 | 0.100 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.100 |
Why?
| | Ubiquitin | 1 | 2012 | 57 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 74 | 0.100 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 139 | 0.100 |
Why?
| | Phytotherapy | 1 | 2012 | 66 | 0.100 |
Why?
| | Capillaries | 2 | 2009 | 91 | 0.100 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.100 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 523 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 603 | 0.090 |
Why?
| | Genetic Testing | 1 | 2013 | 380 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 797 | 0.090 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 56 | 0.090 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.090 |
Why?
| | Cell Differentiation | 2 | 2015 | 1700 | 0.090 |
Why?
| | ROC Curve | 2 | 2017 | 447 | 0.090 |
Why?
| | Collagen | 1 | 2012 | 416 | 0.090 |
Why?
| | After-Hours Care | 1 | 2010 | 15 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2013 | 252 | 0.090 |
Why?
| | Awards and Prizes | 1 | 2011 | 56 | 0.090 |
Why?
| | Mice | 7 | 2022 | 14927 | 0.090 |
Why?
| | Microbiota | 1 | 2017 | 648 | 0.090 |
Why?
| | Autoantibodies | 1 | 2017 | 1354 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4718 | 0.090 |
Why?
| | Organizational Culture | 1 | 2011 | 119 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1398 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 89 | 0.090 |
Why?
| | Peer Group | 1 | 2011 | 203 | 0.080 |
Why?
| | Focus Groups | 1 | 2011 | 385 | 0.080 |
Why?
| | Lung Transplantation | 1 | 2011 | 246 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 331 | 0.080 |
Why?
| | Program Development | 1 | 2011 | 346 | 0.080 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1736 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 233 | 0.080 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 8 | 0.080 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.080 |
Why?
| | Computers | 1 | 2008 | 60 | 0.080 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 115 | 0.080 |
Why?
| | Chest Pain | 1 | 2008 | 81 | 0.080 |
Why?
| | Burn Units | 2 | 2022 | 26 | 0.080 |
Why?
| | Half-Life | 1 | 2008 | 143 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 1857 | 0.080 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 314 | 0.070 |
Why?
| | Schools | 1 | 2011 | 400 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 1721 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 385 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 250 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 164 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 127 | 0.070 |
Why?
| | Patient Readmission | 3 | 2019 | 606 | 0.070 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 4411 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 24 | 0.070 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 515 | 0.070 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 107 | 0.070 |
Why?
| | Georgia | 2 | 2004 | 62 | 0.070 |
Why?
| | Cell Separation | 3 | 2016 | 291 | 0.070 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1028 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2007 | 99 | 0.070 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 122 | 0.070 |
Why?
| | Respiration Disorders | 1 | 2007 | 68 | 0.070 |
Why?
| | Body Fluids | 1 | 2007 | 58 | 0.070 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 149 | 0.070 |
Why?
| | Thrombocytopenia | 2 | 2019 | 178 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 137 | 0.070 |
Why?
| | Program Evaluation | 1 | 2011 | 825 | 0.070 |
Why?
| | Propensity Score | 2 | 2017 | 224 | 0.070 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 89 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2009 | 1084 | 0.070 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 106 | 0.060 |
Why?
| | Adolescent | 6 | 2022 | 17864 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1747 | 0.060 |
Why?
| | Research Design | 1 | 2011 | 930 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2106 | 0.060 |
Why?
| | Hemorrhage | 2 | 2019 | 618 | 0.060 |
Why?
| | Colorado | 4 | 2022 | 4089 | 0.060 |
Why?
| | Databases, Factual | 2 | 2019 | 1132 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4631 | 0.060 |
Why?
| | Observation | 1 | 2004 | 49 | 0.060 |
Why?
| | Time Factors | 4 | 2018 | 6141 | 0.060 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.060 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 7 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 287 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 27 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 19 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 59 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 73 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 54 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2021 | 2585 | 0.050 |
Why?
| | North America | 1 | 2022 | 259 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 56 | 0.050 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 80 | 0.050 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 1 | 0.050 |
Why?
| | Transcytosis | 1 | 2021 | 9 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3545 | 0.050 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 112 | 0.050 |
Why?
| | Naltrexone | 1 | 2022 | 83 | 0.050 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 208 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 172 | 0.050 |
Why?
| | Cilia | 1 | 2022 | 162 | 0.050 |
Why?
| | Bleomycin | 1 | 2022 | 228 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.050 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 757 | 0.050 |
Why?
| | Containment of Biohazards | 1 | 2020 | 11 | 0.050 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1237 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 3334 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 227 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 56 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2318 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 398 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1591 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 227 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 20 | 0.040 |
Why?
| | Leadership | 1 | 2022 | 295 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 125 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 547 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2018 | 135 | 0.040 |
Why?
| | Illinois | 1 | 2017 | 37 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 130 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 38 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2008 | 2150 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2018 | 127 | 0.040 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| | Administration, Oral | 1 | 2019 | 730 | 0.040 |
Why?
| | Venous Thrombosis | 1 | 2019 | 144 | 0.040 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 72 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2018 | 617 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 299 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 335 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 137 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 29 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 280 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 13 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 348 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 983 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 364 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 225 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 135 | 0.030 |
Why?
| | Risk | 1 | 2018 | 815 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 469 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 835 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 487 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 186 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 776 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 201 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1812 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 209 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 728 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 169 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 814 | 0.030 |
Why?
| | Phylogeny | 1 | 2017 | 796 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 313 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 957 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 26 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 306 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1211 | 0.030 |
Why?
| | Ventilator Weaning | 1 | 2013 | 34 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 12 | 0.030 |
Why?
| | Tidal Volume | 1 | 2013 | 76 | 0.030 |
Why?
| | Biological Transport | 1 | 2014 | 372 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.030 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 24 | 0.030 |
Why?
| | Thymus Gland | 1 | 2014 | 296 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2018 | 480 | 0.030 |
Why?
| | Fibrosis | 1 | 2015 | 454 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 106 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2015 | 449 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2013 | 121 | 0.030 |
Why?
| | Protein Binding | 1 | 2017 | 1898 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2015 | 634 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2212 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 298 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 844 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 436 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 66 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 151 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 79 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 372 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 103 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 394 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1539 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 214 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 527 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 84 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 262 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 94 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 457 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 827 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 300 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1523 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 548 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 61 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 750 | 0.020 |
Why?
| | Amides | 1 | 2010 | 88 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 324 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1572 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 202 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 49 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1046 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 15 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 19 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 25 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 50 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Rats | 1 | 2017 | 4973 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 42 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 32 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 75 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 58 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 79 | 0.020 |
Why?
| | Child | 2 | 2022 | 18407 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 719 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 843 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 22 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 83 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 387 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 248 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 63 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 167 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 866 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 284 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 443 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1214 | 0.020 |
Why?
| | Pyridines | 1 | 2010 | 425 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 305 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1636 | 0.020 |
Why?
| | Trauma Centers | 1 | 2009 | 325 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 512 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 189 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 441 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 287 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 310 | 0.020 |
Why?
| | Telomerase | 1 | 2008 | 206 | 0.020 |
Why?
| | Chondrocytes | 1 | 2008 | 199 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1355 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 381 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 849 | 0.010 |
Why?
| | France | 1 | 2003 | 34 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 958 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 86 | 0.010 |
Why?
| | Washington | 1 | 2003 | 133 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 143 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2191 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1229 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|